Acyclovir Patent Expiration
Acyclovir is Used for treating cold sores caused by the herpes simplex virus. It was first introduced by Bausch Health Us Llc
Acyclovir Patents
Given below is the list of patents protecting Acyclovir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sitavig | US8592434 | Mucoadhesive buccal tablets for the treatment of orofacial herpes | Jun 16, 2030 | Ligand Pharms |
| Sitavig | US8747896 | Mucosal bioadhesive slow release carrier for delivering active principles | Jun 03, 2027 | Ligand Pharms |
| Sitavig | US8791127 | Mucosal bioadhesive slow release carrier for delivering active principles | Mar 23, 2027 | Ligand Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Acyclovir's patents.
Latest Legal Activities on Acyclovir's Patents
Given below is the list recent legal activities going on the following patents of Acyclovir.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Dec, 2025 | US8791127 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Nov, 2025 | US8747896 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Apr, 2025 | US8592434 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Dec, 2021 | US8791127 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Nov, 2021 | US8747896 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Apr, 2021 | US8592434 |
| Email Notification Critical
| 22 Sep, 2020 | US8747896 |
| Mail O.P. Petition Decision | 22 Sep, 2020 | US8747896 |
| Email Notification Critical
| 22 Sep, 2020 | US8791127 |
| Mail O.P. Petition Decision | 22 Sep, 2020 | US8791127 |
Acyclovir's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Acyclovir:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
